The Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) and features dormant and discontinued products.

GlobalData tracks six drugs in development for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) by five companies/universities/institutes. The top development phase for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) is preclinical with two drugs in that stage. The Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline products market are: Alexion Pharmaceuticals, Amgen and Apellis Pharmaceuticals.

The key targets in the Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline products market include Complement Factor D (C3 Convertase Activator or Adipsin or Properdin Factor D or CFD or EC 3.4.21.46), Complement C3 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 1 or C3), and C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1).

The key mechanisms of action in the Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline product include Complement Factor D (C3 Convertase Activator or Adipsin or Properdin Factor D or CFD or EC 3.4.21.46) Inhibitor with three drugs in Phase I. The Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline products market including Small Molecule, and Synthetic Peptide.

Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) overview

Membranoproliferative glomerulonephritis type II (MPGN II) is a rare disease characterized by the presence of abnormal electron-dense deposits within the glomerular basement membrane of the kidney and often within Bruch’s membrane in the eye. MPGN II is also known as “dense deposit disease”. This type is known to be associated with a serum immunoglobulin, C3 nephritic factor (C3NeF), that stabilizes C3 convertase (C3bBb), thereby resulting in persistent activation of the alternative complement pathway.

For a complete picture of Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.